LONDON – Bristol-Myers Squibb's immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.
-
Bristol-Myers to test Opdivo with Nektar drug for several cancers
-
Fatigue keeps many Hodgkin survivors from working
-
8-year-old to walk in fashion show after cancer battle
Opdivo is already approved for melanoma, lung cancer and kidney cancer.